Delving into the Latest Updates on Autologous adipose derived mesenchymal stem cells (Hope Biosciences) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Autologous HBadMSCs, HBadMSC

Target-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

Brain Injuries, TraumaticBrain Injury, ChronicMultiple Sclerosis+ [2]

Inactive Indication

Alzheimer DiseaseCerebral PalsyHuntington Disease+ [7]

Originator Organization

Hope Biosciences LLCStartup

Active Organization

Hope Biosciences LLCStartup

Inactive Organization

University of Texas Health Science Center At San Antonio

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury and/or hypoxic-ischemic encephalopathy in adults.

Start Date16 Apr 2024

Sponsor / Collaborator

Hope Biosciences LLCStartup

NCT05116540 / CompletedPhase 2IIT

A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis

Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period. Study participants will continue their established concomitant medications during participation in this investigation.

Start Date24 Nov 2021

Sponsor / Collaborator-

NCT04928287 / CompletedPhase 2IIT

"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease"

This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
The trial includes a screening period of up to 4 weeks, a 32-week treatment period, and a safety Follow-up period of 20 weeks after the last investigational product administration.
This clinical trial will be open to enroll 24 eligible participants diagnosed with Parkinson's disease. Patients' recruitment will be conducted by the study team, if eligible participants are identified based on eligibility criteria, a screening visit will be scheduled. Informed consent form will be given to the study participants and signed before any study procedures. Informed consent form will include information about the clinical trial and some aspects should be considered during this process.

Start Date28 Jun 2021

Sponsor / Collaborator

Hope Biosciences LLCStartup

100 Clinical Results associated with Autologous adipose derived mesenchymal stem cells (Hope Biosciences)

Login to view more data

100 Translational Medicine associated with Autologous adipose derived mesenchymal stem cells (Hope Biosciences)

Login to view more data

100 Patents (Medical) associated with Autologous adipose derived mesenchymal stem cells (Hope Biosciences)

Login to view more data

6

Literatures (Medical) associated with Autologous adipose derived mesenchymal stem cells (Hope Biosciences)

01 Jan 2023·Frontiers in neurology

Long-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report.

Author: Tripathy, Mallika ; Prossin, Alan ; Chang, Donna ; Kim, Hosu ; Park, Hyeonggeun ; Vij, Ridhima ; Lotfi, Djamchid ; Cheng, Thanh

Parkinson's disease (PD) is a neurodegenerative disease that involves the loss of dopaminergic neurons in the substantia nigra pars compacta of the basal ganglia. Clinically, patient presentation involves a combination of motor and non-motor symptoms characterized by progressive worsening over time and significant decreases in overall quality-of-life. Despite there being no fully restorative cure for PD, Mesenchymal Stem Cell (MSC) therapy offers promising therapeutic potential. Here, we report a case of a 77-year-old female, living with idiopathic Parkinson's Disease for over 17 years. The patient received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs). A total of 26 infusion treatments of HB-adMSCs were administered over the course of ~2 years that resulted in marked improvements in her typical Parkinsonian symptoms, as demonstrated by the decreases in her UPDRS (Unified Parkinson's Disease Rating Scale) scores. Changes in clinical scores mirrored concurrent changes in regional brain metabolism as quantified by FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography), compared to baseline. Long-term, multiple infusions of HB-adMSCs were safely tolerated by the patient without any serious adverse events. Further research is needed to evaluate the safety and efficacy of HB-adMSC therapy for the treatment of PD patients.

01 Jan 2022·Journal of Translational Autoimmunity

Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report

Author: Cheng, Thanh ; Kim, Hosu ; Chang, Donna ; Park, Hyeonggeun ; Tripathy, Mallika ; Vij, Ridhima ; Lotfi, Djamchid

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that involves abnormal activation of immune response, affecting multiple organs, including joints, kidneys, lungs, skin, and the hematopoietic system, thereby impairing their normal function. Despite there being no cure for SLE, Mesenchymal Stem Cell (MSC) therapy offers hope for SLE patients because of its potent role in immunomodulation. Here, we report a case of a 65-year-old female battling with SLE for almost 30 years and on a treatment regimen consisting of several medications. Given the level of immunosuppression associated with conventional SLE treatments, the subject was initially enrolled as a participant in a study protocol designed to provide immune protection against COVID-19. The subject received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs) which significantly improved her SLE symptoms and functionality that led the patient's physician to discontinue her Rituximab regime. Based on her response to HB-adMSC therapy, the subject was approved to receive a set of nine infusion treatments to specifically treat her SLE symptoms. Over the course of ∼ one year, the first six infusions were given on a monthly basis, while the remaining three were administered bimonthly - each with a dose of 200 million HB-adMSCs. Since the beginning of the treatment, the subject showed remarkable improvements in her SLE symptoms, as demonstrated by changes in her SF-36 questionnaire responses, Visual Analog Scale (VAS) scores, and C-Reactive Protein (CRP) measurements; however, worsening of the symptoms was noted later during treatment course (when the frequency of infusions changed to bimonthly). Although the shift in remission-relapse cycle is not fully understood, however, the data suggest that treatment frequency might be the key player. No serious adverse events occurred during the entire treatment period. Further research is needed to evaluate the results of this study.

PLOS ONE

Human adipose-derived mesenchymal stem cells for acute and sub-acute TBI

Article

Author: Park, Hyeonggeun ; Prabhakara, Karthik S ; Dao, An ; Olson, Scott D ; Cox, Charles S ; Toledano-Furman, Naama E ; Arceneaux, Austin Q ; Udtha, Sanjna ; Ruppert, Katherine A

In the U.S., approximately 1.7 million people suffer traumatic brain injury each year, with many enduring long-term consequences and significant medical and rehabilitation costs. The primary injury causes physical damage to neurons, glia, fiber tracts and microvasculature, which is then followed by secondary injury, consisting of pathophysiological mechanisms including an immune response, inflammation, edema, excitotoxicity, oxidative damage, and cell death. Most attempts at intervention focus on protection, repair or regeneration, with regenerative medicine becoming an intensively studied area over the past decade. The use of stem cells has been studied in many disease and injury models, using stem cells from a variety of sources and applications. In this study, human adipose-derived mesenchymal stromal cells (MSCs) were administered at early (3 days) and delayed (14 days) time points after controlled cortical impact (CCI) injury in rats. Animals were routinely assessed for neurological and vestibulomotor deficits, and at 32 days post-injury, brain tissue was processed by flow cytometry and immunohistochemistry to analyze neuroinflammation. Treatment with HB-adMSC at either 3d or 14d after injury resulted in significant improvements in neurocognitive outcome and a change in neuroinflammation one month after injury.

100 Deals associated with Autologous adipose derived mesenchymal stem cells (Hope Biosciences)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Injury, Chronic	Phase 2	US	Hope Biosciences LLCStartup	16 Apr 2024
Multiple Sclerosis	Phase 2	US	-	24 Nov 2021
Parkinson Disease	Phase 2	US	Hope Biosciences LLCStartup	28 Jun 2021
Stroke	Preclinical	US	Hope Biosciences LLCStartup	04 Feb 2021
Huntington Disease	Preclinical	US	Hope Biosciences LLCStartup	02 Feb 2021
Musculoskeletal Pain	Discovery	US	Hope Biosciences LLCStartup	08 Feb 2021
Prostatic Cancer	Discovery	US	Hope Biosciences LLCStartup	26 Jan 2021
Alzheimer Disease	Discovery	US	Hope Biosciences LLCStartup	07 Dec 2019
Brain Injuries, Traumatic	Discovery	US	University of Texas Health Science Center At San Antonio	29 Sep 2019
Rheumatoid Arthritis	Discovery	US	Hope Biosciences LLCStartup	25 Sep 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04928287 (PD, CTgov)	Phase 2	Parkinson Disease	24	Placebo+HB-adMSCs (HB-adMSCs)	bqvmcppdgb(fkfunqpqtf) = sklroslkdj cxuglbjape (gtmjzppory, rjfcrcfkdv - cfdrmmkdhb) View more	-	20 May 2024
NCT04928287 (PD, CTgov)	Phase 2	Parkinson Disease	24	Placebo+HB-adMSCs (Placebo)	bqvmcppdgb(fkfunqpqtf) = egjzdbmdpb cxuglbjape (gtmjzppory, nnvdpsdowy - wkanzvgyua) View more	-	20 May 2024
NCT04349631 (CTgov)	Phase 2	COVID-19	51	HB-adMSCs	wnxrcctmkn(kvuivwacbj) = qmjduotdpr vjgctkvsby (fgpmjtanzp, kiqrenxtqh - nobwqlaqza) View more	-	31 Oct 2023
NCT03691909 (HB-adMSCs, CTgov)	Phase 1/2	Rheumatoid Arthritis	15	HB-adMSCs	cxcvroddsb(ajhnnvgtrg) = vyusuooxgc fiikczurxn (fhsfqgugsa, zvjqhkgdbt - duejfvatby) View more	-	22 Mar 2022